MCID: PNC008
MIFTS: 38

Pancreatic Endocrine Carcinoma malady

Categories: Endocrine diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

Aliases & Descriptions for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 14 69
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 42
Islet Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD10 33 C25.4
ICD9CM 35 157.4
MeSH 42 D018273
NCIt 47 C3770
UMLS 69 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to somatostatinoma and pancreatic islet cell tumors. An important gene associated with Pancreatic Endocrine Carcinoma is SSTR2 (Somatostatin Receptor 2), and among its related pathways/superpathways is Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas and liver, and related phenotype is behavior/neurological.

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Related Disease Score Top Affiliating Genes
1 somatostatinoma 11.0
2 pancreatic islet cell tumors 11.0
3 islet cell tumor 11.0
4 pancreatitis 10.3
5 ascariasis 10.2 SST SSTR2
6 uterine ligament cancer 10.2 SST SSTR2
7 breast secretory carcinoma 10.2 SST SSTR2
8 non specific chronic endometritis 10.2 NCAM1 SYP
9 intrahepatic bile duct adenoma 10.2 NCAM1 SYP
10 postgastrectomy syndrome 10.2 SST SYP
11 glomus tumor 10.2 NCAM1 SYP
12 ampulla of vater mucinous adenocarcinoma 10.2 SSTR2 SYP
13 pemphigus foliaceus 10.2 SST SYP
14 spinal chordoma 10.1 NCAM1 SYP
15 ampullary signet ring cell adenocarcinoma 10.1 NCAM1 SYP
16 hypoparathyroidism-intellectual disability-dysmorphism syndrome 10.1 NCAM1 SYP
17 main bronchus cancer 10.1 NCAM1 SYP
18 movement disease 10.1 NCAM1 SYP
19 ovarian germ cell teratoma 10.1 NCAM1 SYP
20 early-onset parkinson disease 10.1 SST SYP
21 rectum leiomyoma 10.1 NCAM1 SYP
22 adult botryoid rhabdomyosarcoma 10.1 SST SYP
23 superior vena cava syndrome 10.1 NCAM1 SYP
24 fragile x-associated tremor/ataxia syndrome 10.1 NCAM1 SYP
25 pelvic inflammatory disease 10.1 SST SYP
26 anal squamous cell carcinoma 10.1 NCAM1 SYP
27 uterine corpus myxoid leiomyosarcoma 10.1 NCAM1 SYP
28 microsporidiosis 10.1 NCAM1 SYP
29 vulvar alveolar soft part sarcoma 10.1 NCAM1 SYP
30 cowden syndrome 3 10.1 SST SYP
31 tabes dorsalis 10.1 SST SYP
32 trachea sarcoma 10.1 NCAM1 SYP
33 cervical alveolar soft part sarcoma 10.1 SST SSTR2
34 bone dysplasia azouz type 10.1 SST SYP
35 cardioauditory syndrome of sanchez cascos 10.1 SST SYP
36 pancreatic agenesis 10.1 NCAM1 SYP
37 eccrine papillary adenocarcinoma 10.1 SST SYP
38 sternum lymphoma 10.1 NCAM1 SYP
39 sex differentiation disease 10.1 NCAM1 SYP
40 urinary tract papillary transitional cell benign neoplasm 10.1 NCAM1 SYP
41 brachial plexus neuropathy 10.0 NCAM1 SYP
42 peeling skin syndrome 10.0 NCAM1 SYP
43 diffuse cutaneous mastocytosis 10.0 FOXK1 SYP
44 oral leukoedema 10.0 NCAM1 SYP
45 acalculous cholecystitis 10.0 FOXK1 SYP
46 brown-vialetto-van laere syndrome 10.0 NCAM1 SYP
47 mitochondrial complex ii deficiency 10.0 SST SSTR2 SYP
48 rheumatic encephalitis 10.0 SST SSTR5
49 orofaciodigital syndrome iv 10.0 SST SSTR2 SYP
50 endocrine organ benign neoplasm 10.0 SST SYP

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

MGI Mouse Phenotypes related to Pancreatic Endocrine Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.02 FOXK1 NCAM1 SST SSTR2 SYP

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 435)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
5
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
6
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
7
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
8
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
9
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
10
Nicotine Approved Phase 4 54-11-5 942 89594
11
Etomidate Approved Phase 4 33125-97-2 36339 667484
12
Meperidine Approved Phase 4 57-42-1 4058
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
15
Desflurane Approved Phase 4 57041-67-5 42113
16
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
17
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
18 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
23 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
33 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
34 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
36 Hormones Phase 4,Phase 2,Phase 3,Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
38 Antacids Phase 4,Phase 3,Phase 2
39 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
40
Dexlansoprazole Phase 4 138530-94-6, 103577-45-3 9578005
41
Proton pump inhibitors Phase 4,Phase 3,Phase 2
42 Autonomic Agents Phase 4,Phase 1
43 Central Nervous System Stimulants Phase 4
44 Cholinergic Agents Phase 4
45 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Nicotinic Agonists Phase 4
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Adjuvants, Anesthesia Phase 4,Phase 3
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
50 Analgesics, Opioid Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 751)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
4 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4
5 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
6 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
7 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4
8 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4
9 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
10 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
11 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
12 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
13 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
14 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
15 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
16 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma Unknown status NCT00075452 Phase 3
17 Evaluation of A New Digestive Reconstruction Procedure Following Pancreatoduodenectomy Unknown status NCT01931449 Phase 3
18 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
19 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
20 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3
21 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
22 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3
23 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3
24 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3
25 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed NCT00471146 Phase 3
26 Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma Completed NCT00044031 Phase 3
27 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00058149 Phase 3
28 Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer Completed NCT00192712 Phase 2, Phase 3
29 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
30 Early Palliative Care on Quality of Life of Advanced Cancer Patients Completed NCT02988635 Phase 3
31 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3
32 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3
33 Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00088894 Phase 3
34 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
35 New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet Cells Recruiting NCT02127541 Phase 2, Phase 3
36 Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3
37 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3
38 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3
39 A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma Recruiting NCT02539537 Phase 3
40 Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy Recruiting NCT01827553 Phase 3
41 CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy Recruiting NCT02791503 Phase 2, Phase 3
42 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Recruiting NCT02395016 Phase 3
43 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
44 Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects Recruiting NCT02284139 Phase 2, Phase 3
45 Cancer Associated Thrombosis and Isoquercetin (CAT IQ) Recruiting NCT02195232 Phase 2, Phase 3
46 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Recruiting NCT01461850 Phase 3
47 Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas Recruiting NCT02514928 Phase 3
48 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Recruiting NCT02184195 Phase 3
49 Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy Recruiting NCT02404363 Phase 3
50 Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures Recruiting NCT01721174 Phase 2, Phase 3

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

39
Pancreas, Liver

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show all 17)
id Title Authors Year
1
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. ( 27160433 )
2016
2
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. ( 21831734 )
2011
3
Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. ( 21868544 )
2011
4
Pancreatic endocrine carcinoma protruding from the major papilla. ( 20144741 )
2010
5
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. ( 18362846 )
2008
6
A case of multiple hepatic metastases from pancreatic endocrine carcinoma. ( 18573853 )
2008
7
Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. ( 17629086 )
2007
8
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. ( 16364959 )
2006
9
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. ( 17158766 )
2006
10
Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis -- a case report. ( 15849491 )
2005
11
Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. ( 15920550 )
2005
12
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? ( 14962717 )
2004
13
Curative resection for a pancreatic endocrine carcinoma involving the portal vein. ( 15532841 )
2004
14
Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas. ( 11964045 )
2002
15
Pancreatic endocrine carcinoma with multiple hormone production in a raccoon (Procyon lotor). ( 10213674 )
1999
16
Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. ( 1322859 )
1992
17
Pancreatic endocrine carcinoma with ectopic PTH-production and paraneoplastic hypercalcaemia. ( 3082066 )
1986

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

Pathways related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.53 NCAM1 SYP

GO Terms for Pancreatic Endocrine Carcinoma

Cellular components related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.8 SSTR2 SSTR5 SYP

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.43 SST SSTR2 SSTR5
2 response to nutrient GO:0007584 9.37 SST SSTR2
3 digestion GO:0007586 9.32 SST SSTR2
4 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.16 SSTR2 SSTR5
5 cellular response to glucocorticoid stimulus GO:0071385 8.96 SSTR2 SSTR5
6 somatostatin signaling pathway GO:0038170 8.62 SSTR2 SSTR5

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 8.96 SSTR2 SSTR5
2 somatostatin receptor activity GO:0004994 8.62 SSTR2 SSTR5

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....